{"id":551237,"date":"2021-07-05T16:26:01","date_gmt":"2021-07-05T16:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=551237"},"modified":"2021-07-05T16:26:01","modified_gmt":"2021-07-05T16:26:01","slug":"psoriatic-arthritis-market-size-is-expected-to-grow-at-a-cagr-of-65-cagr-during-the-study-period-20182030-by-delveinsight-sun-pharma-global-ucb-biopharma-pfizer-bristolmyers-squibb-etc","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-market-size-is-expected-to-grow-at-a-cagr-of-65-cagr-during-the-study-period-20182030-by-delveinsight-sun-pharma-global-ucb-biopharma-pfizer-bristolmyers-squibb-etc_551237.html","title":{"rendered":"Psoriatic Arthritis Market Size is expected to grow at a CAGR of 6.5% CAGR During the Study Period [2018-2030] by DelveInsight | Sun Pharma Global, UCB Biopharma, Pfizer, Bristol-Myers Squibb, etc"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1625461970.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Psoriatic Arthritis Market Size is expected to grow at a CAGR of 6.5% CAGR During the Study Period [2018-2030] by DelveInsight | Sun Pharma Global, UCB Biopharma, Pfizer, Bristol-Myers Squibb, etc\" src=\"https:\/\/www.abnewswire.com\/uploads\/1625461970.jpeg\" alt=\"Psoriatic Arthritis Market Size is expected to grow at a CAGR of 6.5% CAGR During the Study Period [2018-2030] by DelveInsight | Sun Pharma Global, UCB Biopharma, Pfizer, Bristol-Myers Squibb, etc\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Psoriatic Arthritis Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Psoriatic Arthritis<\/a><\/strong> is a form of arthritis that affects some people who have psoriasis &mdash; a condition that features red patches of skin topped with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but the joint problems can sometimes begin before skin patches appear.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Psoriatic Arthritis Market<\/a><\/strong><strong> Insights, Epidemiology, and Market Forecast-2030&#8243;<\/strong>&nbsp;report delivers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Facts of the Psoriatic Arthritis Market Report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Several key pharmaceutical companies include&nbsp;<strong>AbbVie, Amgen, Pfizer, Bristol-Myers Squibb, Janssen Biotech, Eli Lilly and Company, Novartis, UCB, Sun Pharma Global FZE, AltruBio, and others,<\/strong>&nbsp;are developing novel products to improve the Psoriatic Arthritis treatment outlook.&nbsp;<\/li>\n<li><strong>AbbVie&nbsp;<\/strong>holds the highest Psoriatic Arthritis therapeutic market position among all the current pharma players due to its strategic launch of two candidate drugs&nbsp;<strong>Rinvoq and Skyrizi,<\/strong>&nbsp;in the upcoming years. Both the drugs are already approved in the US and EU markets. Also,&nbsp;<strong>Skyrizi&nbsp;<\/strong>is already approved in Japan.&nbsp;<\/li>\n<li>Psoriatic Arthritis market growth to be ramped up because of the&nbsp;<strong>increased prevalence and growth in the awareness and change in lifestyles<\/strong>&nbsp;that have necessitated the changes in the diagnosis and treatment of Psoriatic Arthritis in the recent decade. The&nbsp;<strong>development of disease models<\/strong>, which might help in the understanding of Psoriatic Arthritis pathophysiology. In addition, the&nbsp;<strong>approval of the multiple drugs<\/strong>&nbsp;has resulted in the entry of the seven different mechanisms of action into the Psoriatic Arthritis market, which has increased the patient response and a change in prescription patterns.&nbsp;<\/li>\n<li>Nevertheless, the Psoriatic Arthritis market growth is threatened by&nbsp;<strong>underdiagnosis or misdiagnosis and limited current Psoriatic Arthritis treatment options&nbsp;<\/strong>in terms of long-term efficacy, tolerability, safety, route of administration, and cost. The entry of the biosimilars has been delayed, and multiple companies have not launched their generics and biosimilars due to the patent rivalry. Safety concerns around JAK inhibitor class have led to regulatory decisions around Rinvoq being delayed for a second time.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Psoriatic Arthritis Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Sun Pharma Global<\/li>\n<li>UCB Biopharma<\/li>\n<li>Pfizer<\/li>\n<li>Bristol-Myers Squibb<\/li>\n<li>AbGenomics<\/li>\n<li>Boehringer Ingelheim<\/li>\n<li>Affibody<\/li>\n<li>AltruBio<\/li>\n<li>Synact Pharma<\/li>\n<li>NeuClone<\/li>\n<li>3SBio<\/li>\n<li>Qyuns Therapeutics<\/li>\n<li>Kangpu Biopharmaceuticals<\/li>\n<li>Alpine Immune Sciences<\/li>\n<li>Avotres<\/li>\n<li>Xbrane Biopharma<\/li>\n<li>XBiotech<\/li>\n<li>Evelo<\/li>\n<li>Luye Pharma Group<\/li>\n<li>Levolta Pharmaceuticals<\/li>\n<li>DNX Biopharmaceuticals<\/li>\n<li>Mycenax Biotech<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Psoriatic Arthritis Market are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Psoriatic Arthritis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Psoriatic Arthritis epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Psoriatic Arthritis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Psoriatic Arthritis market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Psoriatic Arthritis market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Psoriatic Arthritis Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Tildrakizumab<\/li>\n<li>Bimekizumab<\/li>\n<li>PF-06700841<\/li>\n<li>BMS-986165<\/li>\n<li>AbGn-168H<\/li>\n<li>BI 730357<\/li>\n<li>Izokibep<\/li>\n<li>Neihulizumab<\/li>\n<li>AP1189<\/li>\n<li>NeuLara<\/li>\n<li>Apremilast<\/li>\n<li>QX 002N<\/li>\n<li>KPG-612<\/li>\n<li>ALPN 101<\/li>\n<li>AVT001<\/li>\n<li>Xcimzane<\/li>\n<li>RHE 70202<\/li>\n<li>EDP1815<\/li>\n<li>DNX 514<\/li>\n<li>DNX 114<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Psoriatic Arthritis<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Psoriatic Arthritis<\/p>\n<p style=\"text-align: justify;\">4. Psoriatic Arthritis: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Psoriatic Arthritis: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Psoriatic Arthritis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Psoriatic Arthritis Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">13. Psoriatic Arthritis: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Psoriatic Arthritis<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=psoriatic-arthritis-market-size-is-expected-to-grow-at-a-cagr-of-65-cagr-during-the-study-period-20182030-by-delveinsight-sun-pharma-global-ucb-biopharma-pfizer-bristolmyers-squibb-etc\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=psoriatic-arthritis-market-size-is-expected-to-grow-at-a-cagr-of-65-cagr-during-the-study-period-20182030-by-delveinsight-sun-pharma-global-ucb-biopharma-pfizer-bristolmyers-squibb-etc\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Psoriatic Arthritis Market Psoriatic Arthritis is a form of arthritis that affects some people who have psoriasis &mdash; a condition that features red patches of skin topped with silvery scales. Most people develop psoriasis first and are later diagnosed with &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-market-size-is-expected-to-grow-at-a-cagr-of-65-cagr-during-the-study-period-20182030-by-delveinsight-sun-pharma-global-ucb-biopharma-pfizer-bristolmyers-squibb-etc_551237.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-551237","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=551237"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551237\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=551237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=551237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=551237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}